OncoMatch/Clinical Trials/NCT03592472
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Is NCT03592472 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Pazopanib and Abexinostat for renal cell carcinoma.
Treatment: Pazopanib · Abexinostat — This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: vegf tyrosine kinase inhibitor
Lab requirements
Blood counts
adequate baseline hematologic function
Kidney function
adequate baseline organ function
Liver function
adequate baseline organ function
Patients have adequate baseline organ function. Patients have adequate baseline hematologic function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Of UA Cancer Center(UACC)/DH-SJHMC · Phoenix, Arizona
- University of California Davis Comprehensive Cancer Center · Sacramento, California
- UCSF Helen Diller Family Comphrensive Cancer Center - Hemato · San Francisco, California
- Norton Cancer Institute, Norton Healthcare Pavilion · Louisville, Kentucky
- Ochsner Clinic Foundation · New Orleans, Louisiana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify